CRISPR/ViaCyte and Genprex Vie for First Diabetes Gene Therapy

Genome editing has been a hot-button topic in recent years. With the rise of CRISPR technology in the news, this is not surprising for either scientists or investors.

In February 2022, CRISPR Therapeutics and ViaCyte made history, carrying out the first-in-human transplant of gene-edited, stem cell-derived pancreatic cells to treat Type 1 diabetes (T1D).